1887
  1. Home
  2. Eurosurveillance
  3. Volume 27, Issue 44, 03/Nov/2022
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

We evaluated neutralising antibody titres against wild type (WT) SARS-CoV-2 and four Omicron variants (BA.1, BA.2, BA.5 and BA.2.75) in fully vaccinated (three doses of Comirnaty vaccine) healthcare workers (HCW) in Israel who had breakthrough BA.1/BA5 infections. Omicron breakthrough infections in vaccinated individuals resulted in increased neutralising antibodies against the WT and Omicron variants compared with vaccinated uninfected HCW. HCW who recovered from BA.1 or BA.5 infections showed similar neutralising antibodies levels against BA.2.75.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2022.27.44.2200785
2022-11-03
2024-04-26
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2022.27.44.2200785
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/27/44/eurosurv-27-44-3.html?itemId=/content/10.2807/1560-7917.ES.2022.27.44.2200785&mimeType=html&fmt=ahah

References

  1. Mohapatra RK, Kandi V, Verma S, Dhama K. Challenges of the Omicron (B.1.1.529) variant and its lineages: a global perspective. ChemBioChem. 2022;23(9):e202200059.  https://doi.org/10.1002/cbic.202200059  PMID: 35322516 
  2. Kliker L, Zuckerman N, Atari N, Barda N, Gilboa M, Nemet I, et al. COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022. Euro Surveill. 2022;27(30):2200559.  https://doi.org/10.2807/1560-7917.ES.2022.27.30.2200559  PMID: 35904058 
  3. Mohapatra RK, Kandi V, Mishra S, Sarangi AK, Pradhan MK, Mohapatra PK, et al. Emerging novel sub-lineage BA.2.75: The next dominant omicron variant? Int J Surg. 2022;104:106835.  https://doi.org/10.1016/j.ijsu.2022.106835  PMID: 35963574 
  4. Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E, et al. Continued emergence and evolution of Omicron in South Africa: New BA.4 and BA.5 lineages. medRxiv. 2022.05.01.22274406 . https://doi.org/10.1101/2022.05.01.22274406 
  5. Ou J, Lan W, Wu X, Zhao T, Duan B, Yang P, et al. Tracking SARS-CoV-2 Omicron diverse spike gene mutations identifies multiple inter-variant recombination events. Signal Transduct Target Ther. 2022;7(1):138.  https://doi.org/10.1038/s41392-022-00992-2  PMID: 35474215 
  6. Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E, et al. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat Med. 2022;28(9):1785-90.  https://doi.org/10.1038/s41591-022-01911-2  PMID: 35760080 
  7. Yamasoba D, Kimura I, Kosugi Y, Uriu K, Fujita S, Ito J, et al. Neutralisation sensitivity of Omicron BA.2.75 to therapeutic monoclonal antibodies. bioRxiv. 2022;2022.07.14.500041; Preprint.  https://doi.org/10.1101/2022.07.14.500041 
  8. Shaheen N, Mohamed A, Soliman Y, Abdelwahab OA, Diab RA, Desouki MT, et al. Could the new BA.2.75 sub-variant lead to another COVID-19 wave in the world? - Correspondence. Int J Surg. 2022;105:106861.  https://doi.org/10.1016/j.ijsu.2022.106861  PMID: 36031071 
  9. Qu P, Evans JP, Zheng YM, Carlin C, Saif LJ, Oltz EM, et al. Evasion of neutralizing antibody response by the SARS-CoV-2 BA.2.75 variant. bioRxiv2022. Preprint . https://doi.org/10.1101/2022.08.14.503921 
  10. Scarpa F, Sanna D, Azzena I, Giovanetti M, Benvenuto D, Angeletti S, et al. On the SARS-CoV-2 BA.2.75 variant: A genetic and structural point of view. J Med Virol. 2022;jmv.28119.  https://doi.org/10.1002/jmv.28119  PMID: 36059082 
  11. Wang X, Ai J, Li X, Zhao X, Wu J, Zhang H, et al. Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera. Cell Discov. 2022;8(1):110.  https://doi.org/10.1038/s41421-022-00472-5  PMID: 36229428 
Omicron BA.2.75 variant is efficiently neutralised following BA.1 and BA.5 breakthrough infection in vaccinated individuals, Israel, June to September 2022
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Nofar+Atari&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Atari Nofar</a>, <a href="/search?value1=Limor+Kliker&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kliker Limor</a>, <a href="/search?value1=Neta+Zuckerman&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Zuckerman Neta</a>, <a href="/search?value1=Bayan+Abd+Elkader&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Elkader Bayan Abd</a>, <a href="/search?value1=Yael+Weiss-Ottolenghi&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Weiss-Ottolenghi Yael</a>, <a href="/search?value1=Ella+Mendelson&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mendelson Ella</a>, <a href="/search?value1=Yitshak+Kreiss&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kreiss Yitshak</a>, <a href="/search?value1=Gili+Regev-Yochay&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Regev-Yochay Gili</a>, <a href="/search?value1=Michal+Mandelboim&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mandelboim Michal</a></span>. Omicron BA.2.75 variant is efficiently neutralised following BA.1 and BA.5 breakthrough infection in vaccinated individuals, Israel, June to September 2022 . <a href="/content/ecdc">Euro Surveill.</a> 2022;27(44):pii=2200785. <a href="https://doi.org/10.2807/1560-7917.ES.2022.27.44.2200785" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2022.27.44.2200785</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 06 Oct 2022;&nbsp;&nbsp; <span class="generated">Accepted</span>: 02 Nov 2022 </span> </p>
/content/10.2807/1560-7917.ES.2022.27.44.2200785
/content/10.2807/1560-7917.ES.2022.27.44.2200785
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error